Continuing Improvement of Cardiac Sympathetic Activity on I-123 MIBG Scintigraphy in a Patient with Hypertrophic Obstructive Cardiomyopathy After Percutaneous Transluminal Septal Myocardial Ablation

Overview

Journal J Nucl Cardiol

Specialty Cardiology & Vascular Diseases

Date 2008 Sep 2

PMID 18761260

Citations 1

Authors

Satoshi Okayama

Shiro Uemura

Manabu Horii

Hiroyuki Kawata

Yoshihiko Saito

Affiliations

Soon will be listed here.

Citing Articles

Cardiac sympathetic activity in hypertrophic cardiomyopathy and Tako-tsubo cardiomyopathy.

Verschure D, van Eck-Smit B, Somsen G, Verberne H Clin Transl Imaging. 2015; 3(5):379-385.

PMID: 26457274 PMC: 4592489. DOI: 10.1007/s40336-015-0133-z.

References

Elliott P, McKenna W . Hypertrophic cardiomyopathy. Lancet. 2004; 363(9424):1881-91. DOI: 10.1016/S0140-6736(04)16358-7. View

Patel A, Iskandrian A . MIBG imaging. J Nucl Cardiol. 2002; 9(1):75-94. DOI: 10.1067/mnc.2002.121471. View

Matsuo S, Nakamura Y, Tsutamoto T, Kinoshita M . Impairments of myocardial sympathetic activity may reflect the progression of myocardial damage or dysfunction in hypertrophic cardiomyopathy. J Nucl Cardiol. 2002; 9(4):407-12. DOI: 10.1067/mnc.2002.122765. View

Sigwart U . Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995; 346(8969):211-4. DOI: 10.1016/s0140-6736(95)91267-3. View

Terai H, Shimizu M, Ino H, Yamaguchi M, Uchiyama K, Oe K . Changes in cardiac sympathetic nerve innervation and activity in pathophysiologic transition from typical to end-stage hypertrophic cardiomyopathy. J Nucl Med. 2003; 44(10):1612-7. View

Terai H, Shimizu M, Ino H, Yamaguchi M, Hayashi K, Sakata K . Cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy with malignant ventricular tachyarrhythmias. J Nucl Cardiol. 2003; 10(3):304-10. DOI: 10.1016/s1071-3581(03)00362-3. View

Guo H, Wang J, Chen J, Shan J, Lee J, Ueda T . Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and three-year noninvasive follow-up in 18 patients. Can J Cardiol. 2004; 20(8):779-82. View

Ebina T, Takahashi N, Mitani I, Sumita S, Ishigami T, ASHINO K . Clinical implications of cardiac (123)I-meta-iodobenzylguanidine scintigraphy and cardiac natriuretic peptides in patients with heart disease. Nucl Med Commun. 2002; 23(8):795-801. DOI: 10.1097/00006231-200208000-00014. View

Autore C, Bernabo P, Barilla C, Bruzzi P, Spirito P . The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol. 2005; 45(7):1076-80. DOI: 10.1016/j.jacc.2004.12.067. View

10.

Spirito P, Seidman C, McKenna W, Maron B . The management of hypertrophic cardiomyopathy. N Engl J Med. 1997; 336(11):775-85. DOI: 10.1056/NEJM199703133361107. View

11.

Nakajima K, Bunko H, Taki J, Shimizu M, Muramori A, Hisada K . Quantitative analysis of 123I-meta-iodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy. Am Heart J. 1990; 119(6):1329-37. DOI: 10.1016/s0002-8703(05)80183-8. View

12.

Hiasa G, Hamada M, Saeki H, Ogimoto A, Ohtsuka T, Hara Y . Cardiac sympathetic nerve activity can detect congestive heart failure sensitively in patients with hypertrophic cardiomyopathy. Chest. 2004; 126(3):679-86. DOI: 10.1378/chest.126.3.679. View